923564-33-4

Upstream product

• 186431-96-9 (+/-)-2-tert-Butoxycarbonylamino-3-(2-fluoro-phenyl)-propionic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 2629-55-2 2-fluoro-DL-phenylalanine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 923564-06-1 (4R,5S)-4-(2-fluoro-benzyl)-2,2-dimethyl-5-(3-methylcarbamoyl-pyridin-2-ylmethyl)-oxazolidine-3-carboxylic acid tert-butyl ester 
• 923563-67-1 2-[(4R,5S)-3-tert-butoxycarbonyl-4-(2-fluoro-benzyl)-2,2-dimethyl-oxazolidin-5-ylmethyl]-nicotinic acid 
• 923563-68-2 2-[(4R,5S)-3-tert-butoxycarbonyl-4-(2-fluoro-benzyl)-2,2-dimethyl-oxazolidin-5-ylmethyl]-nicotinic acid methyl ester 
• 923563-66-0 2-[3-tert-butoxycarbonylamino-4-(2-fluoro-phenyl)-2-hydroxy-butyl]-nicotinic acid 
• 923563-65-9 2-[3-tert-butoxycarbonylamino-4-(2-fluoro-phenyl)-2-oxo-butyl]-nicotinic acid 

Relevant academic research and scientific papers

METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS

Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.